A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer

Saiama N. Waqar, Clifford Robinson, Jeffrey Bradley, Boone Goodgame, Melissa Rooney, Kristina Williams, Feng Gao, Ramaswamy Govindan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background The addition of targeted agents to thoracic radiation has not improved outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC). To improve cure rates in locally advanced NSCLC, effective targeted therapies need to be identified that can be given safely with radiation therapy. Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway and has single-agent activity in lung cancer. Inhibition of the mTOR pathway has been found to augment the cytotoxic effect of radiation in preclinical studies. There is scant clinical experience with mTOR inhibitors and radiation. Patients and Methods This was a phase I study evaluating the combination of temsirolimus with thoracic radiation in patients with NSCLC. Results Ten patients were enrolled in the study. The dose-limiting toxicities included sudden death, pneumonitis, and pulmonary hemorrhage. The maximum tolerated dose of temsirolimus that could be administered safely with concurrent radiotherapy (35 Gy in 14 daily fractions) was 15 mg intravenously weekly. Of the 8 evaluable patients, 3 had a partial response and 2 had stable disease. Conclusion The combination of temsirolimus 15 mg weekly and thoracic radiation is well tolerated and warrants further investigation, perhaps in a molecularly defined subset of patients.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalClinical Lung Cancer
Volume15
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Thorax
Radiation
Sirolimus
Radiotherapy
Maximum Tolerated Dose
Radiation Effects
Sudden Death
temsirolimus
Lung Neoplasms
Pneumonia
Hemorrhage
Lung

Keywords

  • Non-small-cell lung cancer
  • Radiation
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Waqar, S. N., Robinson, C., Bradley, J., Goodgame, B., Rooney, M., Williams, K., ... Govindan, R. (2014). A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer. Clinical Lung Cancer, 15(2), 119-123. https://doi.org/10.1016/j.cllc.2013.11.007

A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer. / Waqar, Saiama N.; Robinson, Clifford; Bradley, Jeffrey; Goodgame, Boone; Rooney, Melissa; Williams, Kristina; Gao, Feng; Govindan, Ramaswamy.

In: Clinical Lung Cancer, Vol. 15, No. 2, 03.2014, p. 119-123.

Research output: Contribution to journalArticle

Waqar, SN, Robinson, C, Bradley, J, Goodgame, B, Rooney, M, Williams, K, Gao, F & Govindan, R 2014, 'A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer', Clinical Lung Cancer, vol. 15, no. 2, pp. 119-123. https://doi.org/10.1016/j.cllc.2013.11.007
Waqar SN, Robinson C, Bradley J, Goodgame B, Rooney M, Williams K et al. A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer. Clinical Lung Cancer. 2014 Mar;15(2):119-123. https://doi.org/10.1016/j.cllc.2013.11.007
Waqar, Saiama N. ; Robinson, Clifford ; Bradley, Jeffrey ; Goodgame, Boone ; Rooney, Melissa ; Williams, Kristina ; Gao, Feng ; Govindan, Ramaswamy. / A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer. In: Clinical Lung Cancer. 2014 ; Vol. 15, No. 2. pp. 119-123.
@article{d9d1f8696b2e4cc2a8c7bed5f438f406,
title = "A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer",
abstract = "Background The addition of targeted agents to thoracic radiation has not improved outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC). To improve cure rates in locally advanced NSCLC, effective targeted therapies need to be identified that can be given safely with radiation therapy. Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway and has single-agent activity in lung cancer. Inhibition of the mTOR pathway has been found to augment the cytotoxic effect of radiation in preclinical studies. There is scant clinical experience with mTOR inhibitors and radiation. Patients and Methods This was a phase I study evaluating the combination of temsirolimus with thoracic radiation in patients with NSCLC. Results Ten patients were enrolled in the study. The dose-limiting toxicities included sudden death, pneumonitis, and pulmonary hemorrhage. The maximum tolerated dose of temsirolimus that could be administered safely with concurrent radiotherapy (35 Gy in 14 daily fractions) was 15 mg intravenously weekly. Of the 8 evaluable patients, 3 had a partial response and 2 had stable disease. Conclusion The combination of temsirolimus 15 mg weekly and thoracic radiation is well tolerated and warrants further investigation, perhaps in a molecularly defined subset of patients.",
keywords = "Non-small-cell lung cancer, Radiation, Temsirolimus",
author = "Waqar, {Saiama N.} and Clifford Robinson and Jeffrey Bradley and Boone Goodgame and Melissa Rooney and Kristina Williams and Feng Gao and Ramaswamy Govindan",
year = "2014",
month = "3",
doi = "10.1016/j.cllc.2013.11.007",
language = "English (US)",
volume = "15",
pages = "119--123",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - A phase i study of temsirolimus and thoracic radiation in non-small-cell lung cancer

AU - Waqar, Saiama N.

AU - Robinson, Clifford

AU - Bradley, Jeffrey

AU - Goodgame, Boone

AU - Rooney, Melissa

AU - Williams, Kristina

AU - Gao, Feng

AU - Govindan, Ramaswamy

PY - 2014/3

Y1 - 2014/3

N2 - Background The addition of targeted agents to thoracic radiation has not improved outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC). To improve cure rates in locally advanced NSCLC, effective targeted therapies need to be identified that can be given safely with radiation therapy. Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway and has single-agent activity in lung cancer. Inhibition of the mTOR pathway has been found to augment the cytotoxic effect of radiation in preclinical studies. There is scant clinical experience with mTOR inhibitors and radiation. Patients and Methods This was a phase I study evaluating the combination of temsirolimus with thoracic radiation in patients with NSCLC. Results Ten patients were enrolled in the study. The dose-limiting toxicities included sudden death, pneumonitis, and pulmonary hemorrhage. The maximum tolerated dose of temsirolimus that could be administered safely with concurrent radiotherapy (35 Gy in 14 daily fractions) was 15 mg intravenously weekly. Of the 8 evaluable patients, 3 had a partial response and 2 had stable disease. Conclusion The combination of temsirolimus 15 mg weekly and thoracic radiation is well tolerated and warrants further investigation, perhaps in a molecularly defined subset of patients.

AB - Background The addition of targeted agents to thoracic radiation has not improved outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC). To improve cure rates in locally advanced NSCLC, effective targeted therapies need to be identified that can be given safely with radiation therapy. Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway and has single-agent activity in lung cancer. Inhibition of the mTOR pathway has been found to augment the cytotoxic effect of radiation in preclinical studies. There is scant clinical experience with mTOR inhibitors and radiation. Patients and Methods This was a phase I study evaluating the combination of temsirolimus with thoracic radiation in patients with NSCLC. Results Ten patients were enrolled in the study. The dose-limiting toxicities included sudden death, pneumonitis, and pulmonary hemorrhage. The maximum tolerated dose of temsirolimus that could be administered safely with concurrent radiotherapy (35 Gy in 14 daily fractions) was 15 mg intravenously weekly. Of the 8 evaluable patients, 3 had a partial response and 2 had stable disease. Conclusion The combination of temsirolimus 15 mg weekly and thoracic radiation is well tolerated and warrants further investigation, perhaps in a molecularly defined subset of patients.

KW - Non-small-cell lung cancer

KW - Radiation

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84894101093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894101093&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.11.007

DO - 10.1016/j.cllc.2013.11.007

M3 - Article

VL - 15

SP - 119

EP - 123

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -